Loading...
•
Jun 30, 2024
Adaptimmune Q2 2024 Earnings Report
Adaptimmune reported financial results and business updates.
Key Takeaways
Adaptimmune reported Q2 2024 financial results, highlighted by FDA approval for Tecelra and revenue increase due to the Genentech collaboration termination. The company had a net profit of $69.5 million and total liquidity of $214.8 million.
Received U.S. FDA accelerated approval of Tecelra® (afami-cel).
Patients can start their treatment journey with biomarker testing available.
Adaptimmune systems are ready to receive orders for Tecelra.
Total Liquidity of $214.8 million at the end of Q2.
Forward Guidance
Adaptimmune expects its sarcoma franchise to redefine the treatment landscape in advanced soft tissue sarcoma with projected peak US sales of $400 million.
Positive Outlook
- Tecelra received US FDA approval.
- Patients can start their treatment journey now.
- Ordering platform is up and running.
- Tecelra will be available in 6-10 US authorized treatment centers.
- Plans to commence rolling BLA submission for lete-cel in 2025 and commercial launch in 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...